Type IX Collagen Turnover Is Altered in Patients with Solid Tumors.

Autor: Port, Helena, He, Yi, Karsdal, Morten A., Madsen, Emilie A., Bay-Jensen, Anne-Christine, Willumsen, Nicholas, Holm Nielsen, Signe
Předmět:
Zdroj: Cancers; Jun2024, Vol. 16 Issue 11, p2035, 11p
Abstrakt: Simple Summary: The extracellular matrix, composed of various collagens including the fibril-associated collagens with interrupted triple helices (FACIT), plays a crucial role in cancer development and progression. Type IX collagen belongs to the FACIT family, yet its specific role in cancer biology remains unclear. Understanding the impact of collagen type IX in the tumor microenvironment can provide insights into how changes in the ECM contribute to cancer development and metastasis. By identifying biomarkers derived from type IX collagen turnover that reflect ECM alterations, we can quantify these changes and better understand cancer pathogenesis. This article introduces a type IX collagen biomarker that could serve as a diagnostic tool for various types of solid tumors. The fibrotic tumor microenvironment, characterized by its intricate extracellular matrix (ECM), consists of many collagens with diverse functions and unexplored biomarker potential. Type IX collagen is a member of the low-abundance collagen family known as the fibril-associated collagen with interrupted triple helices (FACITs) and is found mostly in cartilage. Its role in the tumor microenvironment remains unexplored. To investigate the biomarker potential of a type IX collagen in cancer, an immuno-assay was developed (PRO-C9) and technical assay performance was evaluated for the assessment of serum. PRO-C9 levels were measured in serum samples from 259 patients with various solid tumor types compared to serum levels from 73 healthy controls. PRO-C9 levels were significantly elevated in patients with solid tumors including bladder, breast, colorectal, gastric, head and neck, lung, melanoma, ovarian, pancreatic, and renal compared to levels in healthy controls (p < 0.05–p < 0.0001). PRO-C9 could discriminate between patients with cancer and healthy controls, with the area under the receiver operating characteristic values ranging from 0.58 to 0.86 (p < 0.3–p < 0.0001), indicating potential diagnostic utility. This study suggests that type IX collagen turnover is altered in patients with solid tumors and demonstrates the feasibility of using PRO-C9 as a non-invasive serum-based biomarker with relevance in multiple cancer types. Furthermore, these results underscore the potential utility of PRO-C9 to better elucidate the biology of FACITs in cancers. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje